Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBD SARS-CoV-2 HBsAg VLP vaccine
- Development stage
- Discontinued
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The RBD SARS-CoV-2 HBsAg VLP vaccine (also referred to as COVIVAXX) is an investigational recombinant virus-like particle (VLP) subunit vaccine developed by Accelagen in collaboration with SpyBiotech and the Serum Institute of India for the prevention of COVID-19. The vaccine's active ingredient consists of the SARS-CoV-2 receptor-binding domain (RBD) antigen covalently conjugated to hepatitis B surface antigen (HBsAg) virus-like particles (VLPs) using SpyBiotech's proprietary SpyTag/SpyCatcher transpeptidation system. This "superglue" technology allows for high-density, repetitive display of the RBD antigen on the surface of the HBsAg VLP scaffold, mimicking the viral structure to enhance immunogenicity and stimulate the production of neutralizing anti-RBD antibodies. Formulated with adjuvants such as alum alone or alum combined with CpG 1018, the vaccine is administered intramuscularly. It has been evaluated in Phase 1/2 clinical trials in Australia, though development was stopped early for commercial reasons.
- Brand names
- COVIVAXX
- Other names
- RBD-HBsAg VLP vaccineRBD-VLP vaccine
02
Targets
ACE2 (Angiotensin-converting enzyme 2)B-cell receptor specific for SARS-CoV-2 receptor-binding domainSARS-CoV-2 spike
Beyond the preview
Go deeper on RBD SARS-CoV-2 HBsAg VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBD SARS-CoV-2 HBsAg VLP vaccine.